Slight revision:

The medical meeting panel determined what advice will be provided to the bureaucrats to act on. PEB had managed to get three of the panel members with positive things to say, one from Kaiser Permanente, a large Healthcare provider (with 12 million clients in eight states and DC) that already use PEB tests. There is a wild-card in that RFK is Trump's Health and Human Services chief, though for PEB's good or ill is difficult to determine.

A further Update from PEB, post trading halt:

"Pacific Edge does not control if or when Novitas will develop a new or substantially revised draft LCD supporting the reimbursement of Cxbladder. Pacific Edge maintains the view that generating compelling clinical evidence in a rigid framework of analytical validation, clinical validation and clinical utility and the unmet clinical need as articulated by the expert panel provides Novitas with the appropriate evidence and motivation to develop this policy expediently. Pacific Edge estimates the timelines for draft coverage are within approximately six months and final-effective coverage within a further approximately six months, noting Novitas has up to 12 months from the published draft to finalize or retire any draft LCD."

PEB shares have risen 300% since February last year when the company's medicare charge codes were de-activated, The shares ended with a 6.67% increase on Monday after the trading halt. The shares were first introduced at 12 cents in 2003, and have peaked in the $1.50 range twice in 2014 and 2021.